Any current/future new fundraising through debt or equity?

No explicit mention of any current or future fundraising through debt or equity is provided in the transcript. The company discusses significant ongoing and planned capital expenditures (capex) around INR 500 crores for Site 3++ and Site 5, with capitalization expected in the near term. There is an emphasis on managing working capital efficiently, which currently stands around 160 days. No guidance or comments were made about raising additional funds through debt or equity during the call. The management seems focused on organic growth funded through operations and capex planning rather than e

Any current/future capex/capital investment/strategic investment?

Capex done so far in 9 months: Approximately INR 500 crores for Site 3++ and Site 5 (Panoli). Full year capex expected: Approximately INR 450-500 crores. Site 3++ capex: Approximately INR 260 crores. Phase 1 (2 blocks) of Site 5 expected to be ready and capitalized within the year. Future capacity additions: Plan to expand Converge polyol capacity to 2 KTA (2,000 tonnes per annum). Monitoring inbound inquiries to fast-track expansions if necessary. Strategy allows for capitalizing on the current pipeline and scaling up assets as required.

Future growth expectations in sales/revenue/volumes?

Baker Hughes business is trending upwards with 20% quarter-on-quarter growth in Q3 FY26, expected to continue increasing as more sites and products are added. Large scale manufacturing (LSM) volume growth is over 10% quarter-on-quarter and 25% year-on-year; additional new products added in Site 5 targeted at pharma and agro sectors. Converge polyol sales continue to increase, with good demand expected for FY26 and FY27; target to expand capacity to 2 KTA (~2,000 tonnes) in coming years. New marquee clients added in LSM segment, with commercial production soon from Site 5 products. Otsuka Chemi

Future growth expectations in earnings/operating earnings/profits/EPS?

Revenue from Baker Hughes is trending upwards with 20% quarter-on-quarter growth in Q3 FY26, expected to continue growing through FY27 as product offerings and site coverage expand. Large-scale manufacturing volume growth is over 25% year-on-year and 10% quarter-on-quarter, indicating strong demand and volume ramp-up. EBITDA margins are expected around 29-30%, considering a conservative estimate without one-time income. CRAMS segment has high margins of 60%-65%, CEM margins between 27%-30%, and LSM margins between 21%-23%, shaping overall profitability. CEM and CRAMS expected to contribute 70%

Current/ Expected Orderbook/ Pending Orders?

The company currently services Baker Hughes with 8 products in commercial production (Site 4) generating a run rate of INR 60 crores this quarter. There are an additional 7 to 8 products in the pipeline under research and scale-up stages. Management refrains from commenting on the potential market size or forward-looking orderbook details. Contract manufacturing (CRAMS) clients may pay advances or require Aether to invest upfront on strategic long-term projects. Contracts generally span 5 to 10 years and auto-renew, with pricing negotiated annually. The company aims to grow its strategic partn

IN US

Sale is live|00:00:00left today

Aether Industries LtdQ4 FY27Chemicals & Petrochemicals

Aether Industries Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,325P/E: 65.2Market Cap: ₹14.7K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Baker Hughes business is trending upwards with 20% quarter-on-quarter growth in Q3 FY26, expected to continue increasing as more sites and products are added.
→Large scale manufacturing (LSM) volume growth is over 10% quarter-on-quarter and 25% year-on-year; additional new products added in Site 5 targeted at pharma and agro sectors.
→Converge polyol sales continue to increase, with good demand expected for FY26 and FY27; target to expand capacity to 2 KTA (~2,000 tonnes) in coming years.
→New marquee clients added in LSM segment, with commercial production soon from Site 5 products.
→Otsuka Chemical contract expected to deliver INR 35-40 crores sales in FY26.
→Semiconductor electronic chemicals validation batches dispatched, with potential growth from these advanced products.
→Overall, management is optimistic of sustained volume and revenue growth driven by expanding product pipelines, strategic partnerships, and capacity ramp-ups over the next 1-3 years.

Margin guidance

Category 3

→Revenue from Baker Hughes is trending upwards with 20% quarter-on-quarter growth in Q3 FY26, expected to continue growing through FY27 as product offerings and site coverage expand.
→Large-scale manufacturing volume growth is over 25% year-on-year and 10% quarter-on-quarter, indicating strong demand and volume ramp-up.
→EBITDA margins are expected around 29-30%, considering a conservative estimate without one-time income.
→CRAMS segment has high margins of 60%-65%, CEM margins between 27%-30%, and LSM margins between 21%-23%, shaping overall profitability.
→CEM and CRAMS expected to contribute 70% of revenues in medium term, increasing higher-margin business share.
→New products and capacity expansions (Site 3++ and Site 5) poised to ramp up, with utilization targets of 45%-50% (Site 3++) and 35%-40% (Site 5) in FY27.
→Management refrains from explicit forward guidance but indicates a positive and growing trend in revenues and margins.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any current or future fundraising through debt or equity is provided in the transcript.
→The company discusses significant ongoing and planned capital expenditures (capex) around INR 500 crores for Site 3++ and Site 5, with capitalization expected in the near term.
→There is an emphasis on managing working capital efficiently, which currently stands around 160 days.
→No guidance or comments were made about raising additional funds through debt or equity during the call.
→The management seems focused on organic growth funded through operations and capex planning rather than external fundraising at this stage.

Order book

→The company currently services Baker Hughes with 8 products in commercial production (Site 4) generating a run rate of INR 60 crores this quarter.
→There are an additional 7 to 8 products in the pipeline under research and scale-up stages.
→Management refrains from commenting on the potential market size or forward-looking orderbook details.
→Contract manufacturing (CRAMS) clients may pay advances or require Aether to invest upfront on strategic long-term projects.
→Contracts generally span 5 to 10 years and auto-renew, with pricing negotiated annually.
→The company aims to grow its strategic partnerships, especially with Baker Hughes, across a broader portfolio of products over the next decades.
→No explicit total order book or pending order quantum was disclosed in the call transcript.

Capex plans

Yes

→Capex done so far in 9 months: Approximately INR 500 crores for Site 3++ and Site 5 (Panoli).
→Full year capex expected: Approximately INR 450-500 crores.
→Site 3++ capex: Approximately INR 260 crores.
→Phase 1 (2 blocks) of Site 5 expected to be ready and capitalized within the year.
→Future capacity additions: Plan to expand Converge polyol capacity to 2 KTA (2,000 tonnes per annum).
→Monitoring inbound inquiries to fast-track expansions if necessary.
→Strategy allows for capitalizing on the current pipeline and scaling up assets as required.

How does Aether Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aether Industries Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Aether Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio